Aurora Innovation, BYD, and Tempus AI are just three of Lingotto Innovation’s holdings with explosive growth potential.

AstraZeneca’s AI algorithms, developed based on biomarkers and diagnosis data points, have shown promise in broadening the ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Artificial intelligence allows us to examine that data to identify certain types of heart disease sooner and get personalized ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

The Chicago-based Tempus spinout called the financing round a major milestone as it expands its AI-enabled platform.

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...